Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998014562> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W1998014562 endingPage "798" @default.
- W1998014562 startingPage "793" @default.
- W1998014562 abstract "Abstract Context Metastatic renal cell carcinoma (mRCC) is particularly resistant to conventional treatments. Improved understanding of the molecular pathways involved in mRCC has led to the development of novel targeted therapies for this disease. Objective This review describes key molecular pathways that have emerged as therapeutic targets for mRCC. Particular emphasis is placed on the mammalian target of rapamycin (mTOR) pathway and the newer class of targeted agents (ie, mTOR inhibitors). Evidence acquisition Medical literature was retrieved from PubMed during January 2009. Additional relevant articles were included from the bibliographies of retrieved literature. Evidence synthesis The von Hippel-Lindau (VHL) tumour suppressor gene was discovered in 1993 and has a vital role in renal cell carcinoma (RCC) pathogenesis. VHL mutations lead to accumulation of hypoxia-inducible factors (HIFs) that stimulate overexpression of the proangiogenic vascular endothelial growth factor (VEGF). The mTOR pathway was subsequently identified, which regulates cell growth, proliferation, and angiogenesis, and also has a pivotal role in RCC. An increase in HIF expression is a product of the mTOR pathway. Therefore, agents that suppress the mTOR pathway have become the focus of much research. Such mTOR inhibitors as everolimus and temsirolimus have shown robust clinical efficacy in treating mRCC. For example, everolimus has proved effective in patients whose disease has progressed after treatment with VEGF-targeted therapy. Conclusions Targeted agents against components of the mTOR pathway are in clinical use and have improved outcomes for patients with advanced disease and poor prognosis or with advanced disease that has become refractory to sunitinib or sorafenib." @default.
- W1998014562 created "2016-06-24" @default.
- W1998014562 creator A5002039384 @default.
- W1998014562 creator A5040832651 @default.
- W1998014562 date "2009-11-01" @default.
- W1998014562 modified "2023-09-25" @default.
- W1998014562 title "Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors" @default.
- W1998014562 cites W1978173977 @default.
- W1998014562 cites W1997050190 @default.
- W1998014562 cites W1999966467 @default.
- W1998014562 cites W2022201364 @default.
- W1998014562 cites W2024036382 @default.
- W1998014562 cites W2046507292 @default.
- W1998014562 cites W2049491093 @default.
- W1998014562 cites W2052368352 @default.
- W1998014562 cites W2068555261 @default.
- W1998014562 cites W2094159326 @default.
- W1998014562 cites W2098176107 @default.
- W1998014562 cites W2100669312 @default.
- W1998014562 cites W2118677643 @default.
- W1998014562 cites W2127768463 @default.
- W1998014562 cites W2127931911 @default.
- W1998014562 cites W2131818083 @default.
- W1998014562 cites W2135139265 @default.
- W1998014562 cites W2149456801 @default.
- W1998014562 cites W2150162153 @default.
- W1998014562 cites W2153867442 @default.
- W1998014562 cites W2155012968 @default.
- W1998014562 cites W2161628561 @default.
- W1998014562 cites W2162407658 @default.
- W1998014562 doi "https://doi.org/10.1016/j.eursup.2009.08.001" @default.
- W1998014562 hasPublicationYear "2009" @default.
- W1998014562 type Work @default.
- W1998014562 sameAs 1998014562 @default.
- W1998014562 citedByCount "3" @default.
- W1998014562 countsByYear W19980145622013 @default.
- W1998014562 countsByYear W19980145622016 @default.
- W1998014562 crossrefType "journal-article" @default.
- W1998014562 hasAuthorship W1998014562A5002039384 @default.
- W1998014562 hasAuthorship W1998014562A5040832651 @default.
- W1998014562 hasConcept C143998085 @default.
- W1998014562 hasConcept C2777472916 @default.
- W1998014562 hasConcept C502942594 @default.
- W1998014562 hasConcept C71924100 @default.
- W1998014562 hasConceptScore W1998014562C143998085 @default.
- W1998014562 hasConceptScore W1998014562C2777472916 @default.
- W1998014562 hasConceptScore W1998014562C502942594 @default.
- W1998014562 hasConceptScore W1998014562C71924100 @default.
- W1998014562 hasIssue "10" @default.
- W1998014562 hasLocation W19980145621 @default.
- W1998014562 hasOpenAccess W1998014562 @default.
- W1998014562 hasPrimaryLocation W19980145621 @default.
- W1998014562 hasRelatedWork W1994903659 @default.
- W1998014562 hasRelatedWork W1997169225 @default.
- W1998014562 hasRelatedWork W2005149537 @default.
- W1998014562 hasRelatedWork W2045737731 @default.
- W1998014562 hasRelatedWork W2091009781 @default.
- W1998014562 hasRelatedWork W2096517981 @default.
- W1998014562 hasRelatedWork W2360810719 @default.
- W1998014562 hasRelatedWork W2362434115 @default.
- W1998014562 hasRelatedWork W2968450929 @default.
- W1998014562 hasRelatedWork W3039871065 @default.
- W1998014562 hasVolume "8" @default.
- W1998014562 isParatext "false" @default.
- W1998014562 isRetracted "false" @default.
- W1998014562 magId "1998014562" @default.
- W1998014562 workType "article" @default.